Robert McCuaig completed his PhD in molecular epigenetics and molecular biology with a focus on melanoma and breast cancer at the University of Canberra in 2019. He then worked as a research officer at QIMRb, focused on projects examining the interplay of epigenetics and SARS-CoV-2 as well as investigating novel biomarkers for cancer diagnostics. He is now in the Chappell Group working as a Senior Research Assistant on the ViceBio project.


Bachelor of Science (Honours)

PhD (Epigenetics and Molecular Biology)


Tu, W.J., McCuaig, R.D., Melino, M. et al. Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. Cell Discov 7, 37 (2021).